Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease

• John Marshall ,

  * E-mail: john.marshall@genzyme.com

  Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Karen M. Ashe,

  Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Dinesh Bangari,

  Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• KerryAnne McEachern,

  Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Wei-Lien Chuang,

  Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Joshua Pacheco,

  Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Diane P. Copeland,

  Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Robert J. Desnick,

  Affiliation Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, United States of America

  ⨯
• James A. Shayman,

  Affiliation Internal Medicine – Nephrology, Genzyme Corporation, University of Michigan, Ann Arbor, Michigan, United States of America

  ⨯
• Ronald K. Scheule,

  Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Seng H. Cheng

  Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯